Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

被引：0

作者：

Yue-qin Wang

Ai-jun Shen

Jing-ya Sun

Xin Wang

Hong-chun Liu

Min-min Zhang

Dan-qi Chen

Bing Xiong

Jing-kang Shen

Mei-yu Geng

Min Zheng

Jian Ding

机构：

[1] China Pharmaceutical University,Department of New Drug Screening Center

[2] Division of Anti-tumor Pharmacology,Department of Thoracic Surgery

[3] Synthetic Organic and Medicinal Chemistry Laboratory,undefined

[4] State Key Laboratory of Drug Research,undefined

[5] Shanghai Institute of Materia Medica,undefined

[6] Chinese Academy of Sciences,undefined

[7] Shanghai Tongren Hospital,undefined

[8] Shanghai Jiao Tong University School of Medicine,undefined

来源：

Acta Pharmacologica Sinica | 2016年 / 37卷

关键词：

non-small cell lung cancer; gefitinib resistance; Hsp90;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1587 / 1596

页数：9

共 50 条

[1] Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Wang, Yue-qin
Shen, Ai-jun
Sun, Jing-ya
Wang, Xin
Liu, Hong-chun
Zhang, Min-min
Chen, Dan-qi
Xiong, Bing
Shen, Jing-kang
Geng, Mei-yu
Zheng, Min
Ding, Jian
ACTA PHARMACOLOGICA SINICA, 2016, 37 (12) : 1587 - 1596
[2] Discovery of Licochalcone A as a Natural Product Inhibitor of Hsp90 and Its Effect on Gefitinib Resistance in Non-Small Cell Lung Cancer (NSCLC)
Seo, Young Ho
BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (06) : 1917 - 1920
[3] Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib
Wang, Liman
Fan, Yingjuan
Mei, Hanhao
Liu, Yang
Zhang, Lianru
Xu, Jianhua
Huang, Xuhui
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 8937 - 8945
[4] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
Naito, Yoichi
Goto, Koichi
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
[5] The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Smith, Donald L.
Acquaviva, Jaime
Sequeira, Manuel
Jimenez, John-Paul
Zhang, Chaohua
Sang, Jim
Bates, Richard C.
Proia, David A.
TARGETED ONCOLOGY, 2015, 10 (02) : 235 - 245
[6] Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
Proia, David A.
Sang, Jim
He, Suqin
Smith, Donald L.
Sequeira, Manuel
Zhang, Chaohua
Liu, Yuan
Ye, Shuxia
Zhou, Dan
Blackman, Ronald K.
Foley, Kevin P.
Koya, Keizo
Wada, Yumiko
INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2201 - 2209
[7] Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
Jeong, Chul-Ho
Park, Hee Baek
Jang, Won Jun
Jung, Su Hyun
Seo, Young Ho
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 224 - 227
[8] The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Donald L. Smith
Jaime Acquaviva
Manuel Sequeira
John-Paul Jimenez
Chaohua Zhang
Jim Sang
Richard C. Bates
David A. Proia
Targeted Oncology, 2015, 10 : 235 - 245
[9] PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH EGFR-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC
Barlesi, Fabrice
Besse, Benjamin
Chu, Quincy
Gandhi, Leena
Griesinger, Frank
Felip, Enriqueta
Kang, Jin Hyoung
Kim, Sang-We
Rosell, Rafael
Sequist, Lecia V.
Soo, Ross
Wallmark, John
Avsar, Emin
Ofosu-Appiah, William
Pain, Scott
Akimov, Mikhail
Garon, Edward B.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S611 - S612
[10] Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
Fan, Xing-Xing
Li, Na
Wu, Jian-Lin
Zhou, Yan-Ling
He, Jian-Xing
Liu, Liang
Leung, Elaine Lai-Han
MOLECULES, 2014, 19 (03): : 3508 - 3522

← 1 2 3 4 5 →